|Videos|March 28, 2016
Treatment Concerns: Quality of Life
Advertisement
Episodes in this series
Advertisement
Related to this article
Children with diffuse midline glioma who took Keppra lived a median of 20.96 months, compared with 9.92 months for those who did not, a new study found.
Advertisement
Advertisement
Trending on CURE
1
Finding the Words: How to Talk to Someone With Cancer
2
Getting Ready to Swim in a Sea of Pink
3
FDA Approves Bravnetsa, an Equivalent to Lutathera, for GEP-NETs
4
Cancer Research Is Looking Beyond the Tumor to Better Understand the Whole Patient
5